Clifford C Nwaeburu
Overview
Explore the profile of Clifford C Nwaeburu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
264
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nwaeburu C, Abukiwan A, Zhao Z, Herr I
Mol Cancer
. 2023 Aug;
22(1):123.
PMID: 37542316
No abstract available.
2.
Abukiwan A, Nwaeburu C, Bauer N, Zhao Z, Liu L, Gladkich J, et al.
Int J Oncol
. 2023 Jul;
63(2).
PMID: 37417373
Subsequently to the publication of the above article, an interested reader drew to the authors' attention that two pairs of the culture plate images in Fig. 4A-C on p. 60...
3.
Abukiwan A, Nwaeburu C, Bauer N, Zhao Z, Liu L, Gladkich J, et al.
Int J Oncol
. 2018 Nov;
54(1):53-64.
PMID: 30387838
Glucocorticoids (GCs) such as dexamethasone (DEX) are administered as cancer co‑treatment for palliative purposes due to their pro‑apoptotic effects in lymphoid cancer and limited side effects associated with cancer growth...
4.
Yin Y, Liu L, Zhao Z, Yin L, Bauer N, Nwaeburu C, et al.
Cancer Lett
. 2018 Apr;
426:14-24.
PMID: 29627496
Pancreatic ductal adenocarcinoma (PDA) has poor therapeutic options. Recent patient studies indicate that cholesterol-lowering statins have anti-tumor capacities. We examined several established and primary PDA and normal cell lines as...
5.
Liu L, Aleksandrowicz E, Schonsiegel F, Groner D, Bauer N, Nwaeburu C, et al.
Cell Death Dis
. 2017 Oct;
8(10):e3064.
PMID: 28981109
Glucocorticoids such as dexamethasone are widely co-prescribed with cytotoxic therapy because of their proapoptotic effects in lymphoid cancer, reduction of inflammation and edema and additional benefits. Concerns about glucocorticoid-induced therapy...
6.
Nwaeburu C, Abukiwan A, Zhao Z, Herr I
Mol Cancer
. 2017 Feb;
16(1):23.
PMID: 28137273
Background: Cancer stem cells are suggested to contribute to the extremely poor prognosis of pancreatic ductal adenocarcinoma and dysregulation of symmetric and asymmetric stem cell division may be involved. Anticancer...
7.
Nwaeburu C, Bauer N, Zhao Z, Abukiwan A, Gladkich J, Benner A, et al.
Oncotarget
. 2016 Aug;
7(36):58367-58380.
PMID: 27521217
Pancreatic Ductal Adenocarcinoma (PDA) is a highly malignant tumor with poor prognosis. MicroRNAs (miRs) may offer novel therapeutic approaches to treatment. The polyphenol quercetin, present in many fruits and vegetables,...
8.
Fan P, Liu L, Yin Y, Zhao Z, Zhang Y, Amponsah P, et al.
Cancer Lett
. 2016 Feb;
373(1):130-137.
PMID: 26828016
Pancreatic ductal adenocarcinoma (PDA) is among the most lethal malignancies and resistance to chemotherapy prevents the therapeutic outcome. MicroRNAs provide a novel therapeutic strategy. Here, the established and primary human...
9.
Isayev O, Rausch V, Bauer N, Liu L, Fan P, Zhang Y, et al.
Oncotarget
. 2014 Jul;
5(13):5177-89.
PMID: 25015789
According to the cancer stem cell (CSC) hypothesis, the aggressive growth and early metastasis of pancreatic ductal adenocarcinoma (PDA) is due to the activity of CSCs, which are not targeted...
10.
Forster T, Rausch V, Zhang Y, Isayev O, Heilmann K, Schoensiegel F, et al.
Oncotarget
. 2014 Apr;
5(6):1621-34.
PMID: 24742583
The extreme aggressiveness of pancreatic ductal adenocarcinoma (PDA) has been associated with blocked gap junctional intercellular communication (GJIC) and the presence of cancer stem cells (CSCs). We examined whether disturbed...